Signalling profile differences: paliperidone versus risperidone
نویسندگان
چکیده
منابع مشابه
Comparative Pharmacology of Risperidone and Paliperidone
Antipsychotics, risperidone, and risperidone's active metabolite, paliperidone (9-hydroxyrisperidone), are related molecules used for the treatment of schizophrenia and related disorders. Differences in receptor binding, 5-HT2A/D2 (serotonin/dopamine) binding ratios, and mitochondrial proteomics suggest that the effects of risperidone and paliperidone on neuronal firing, regulation of mitochond...
متن کاملRisperidone Induced Amenorrhea Resolved by Paliperidone
*Corresponding author: Cedo D Miljevic, Institute of Mental Health, Palmoticeva 37, 11 000 Belgrade, Serbia, Tel: +381 62 252 317; Fax: +381 11 3239 153; E-mail: [email protected] Received Date: November 11, 2014, Accepted Date: December 15, 2014, Published Date: December 23, 2014 Copyright: © 2015 Cedo D Miljevic, et al., This is an open-access article distributed under the terms of the ...
متن کاملThe Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidone
Some antipsychotic drugs are metabolized in the liver, leading to active metabolites. These metabolites can maintain the effect of the original substrate or display different pharmacokinetic or pharmacodynamic properties, and that can be translated by a different profile of responses and interactions to clinical level. Among these is risperidone, whose active metabolite, 9-OH-risperidone, is kn...
متن کاملDetermination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone
Schizophrenia is a common disease managed by a range of interventions, with the primary treatment being antipsychotic medications (APS). Inadequate response, lack of adherence, and/or adverse events often prevent optimal therapeutic effects or therapeutic efficiency. Monitoring APS plasma concentrations can be used together with a full clinical evaluation to help improve patient care or offer b...
متن کاملPaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
BACKGROUND This post hoc subgroup analysis of a randomized, double-blind trial evaluated the response to treatment with two long-acting injectable atypical antipsychotics, ie, paliperidone palmitate and risperidone long-acting injectable (RLAI), in subjects with schizophrenia experiencing clinically significant symptoms despite recent treatment with oral risperidone only or other oral antipsych...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Pharmacology
سال: 2013
ISSN: 0007-1188
DOI: 10.1111/bph.12295